Investigated for use/treatment in gastrointestinal diseases and disorders (miscellaneous) and autoimmune diseases such as celiac disease.
- Mechanism
- Curator reviewed
ALV003 is an orally administered combination of two proteases engineered to digest gluten. It targets the glutamine and proline residues that are common in gluten. ALV003 consists of a glutamine-specific cysteine protease (EP-B2) and a proline specific prolyl endopeptidase (PEP). The proposed mechanism of action of ALV003 is to digest gluten into non-immunotoxic fragments. [Alvine Pharmaceuticals Press Release]
- Primary indication
- Investigated for use/treatment in gastrointestinal diseases and disorders (miscellaneous) and autoimmune diseases such as celiac disease.Curator reviewed
- Code names
- ALV-003
Resolves to
What you can answer from here — as of February 21, 2021
Which companies are running trials of Latiglutenase, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account